

The background of the entire page is a dark, textured overlay of various financial charts. In the upper right, there is a line chart with a peak and a subsequent decline, labeled with '52.34%'. Below this, there are several bar charts and candlestick patterns, some in blue and some in orange/yellow, set against a grid. The overall aesthetic is professional and data-driven.

HAVEN

EQUITIES

Equity Research Report

Research Standards

HAVEN Report Standards (Mandatory)

1. Structure

- Do not remove sections.
- Pages may be duplicated for depth.
- Every report must include thesis, industry, financials, valuation, risks, and conclusion.

2. Clarity

- Use bullet points, not long paragraphs.
- If crowded → create a new page.
- Visuals > text walls.

3. Evidence

All claims must be supported by:

- Financial data
- Industry comparisons
- Historical performance
- Valuation logic

4. Professional Formatting

- Maintain layout, fonts, and spacing.
- No casual language.
- No opinions without reasoning.

Equity Research Report



TransMedics Group Inc
(TMDX)
Healthcare | Medical Equipment and
Supplies

Written By: Naveen Goyal
Date: 14th April, 2026

This report is prepared by Haven Equities for educational and informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.

Stock Name: TransMedics Group Inc: TMDX

Sector: Healthcare | Industry: Medical Equipment and Supplies | Price: 113.36 USD

Thesis:

TransMedics Group, Inc. (TMDX), a rapidly expanding medical technology company, is revolutionizing organ transplantation with its Organ Care System (OCS), which enhances transportation and preservation. It is a leader in portable organ perfusion and assessment and is based in Andover, Massachusetts. Although there are hazards related to value, regulation, and operational complexity, its technology improves the usage of donor organs and the success of transplants.

Key Drivers:

- OCS Technology Adoption and Rising Transplant volume
- National OCS Program(NOP): Device with Logistics
- Logistics and Aviation network
- Market Expansion: Heart, Liver and Lungs medical equipment.

Key Risks:

- Operational and Logistics risk due to high cost of NOP and Ongoing international expansion (e.g., Italy)
- Due to limited total addressable market risk of growth plateau over time.
- Adoption risk due to Requires transplant centers to shift from traditional "on-ice" methods and revenue scaling due to behavioral and operational change.
- Risk to internal controls, execution, and stability and Challenges in scaling complex operations (NOP model)

Haven Rating: Strong Buy

Recommendation: Strong Buy and Hold

Time Horizon: 3-5 Years

Risk Level: High Risk

Catalyst Driven: Yes

Catalysts (Next 1-6 Months):

In next six months Transmedics Group:

- First international **National OCS Program (NOP)** in Italy during the first half of 2026.
- TMDX roll-out of the Generation 3.0 Organ Care System (OCS) for heart, lung, and liver
- **ENHANCE Heart and DENOVO Lung trials** with clinical trial milestone.
- TMDX is scaling its aviation fleet (**targeting 22+ aircraft**) and piloting "double-shifting" to maximize asset utilization

-Price: 113.36 USD

- P/E Ratio: 23.26

- Market Cap: 3.91 Billion USD

- Enterprise Value: 3.94 Billion USD

- Revenue (TTM): 605.49 Million USD

- Cash: 488.37 Million USD

- FCF: 133.6 Million USD

- Beta (5Y): 2.08

- 52 week low/high: 81.92 USD / 156.00 USD

- Annual Growth (1Y): 68.8(2026 Projection)

Company Snapshot

Business Description: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage, which preserves organs for only 4–6 hours, while OCS extends viability to 8–12+ hours. It has developed three FDA-approved products—OCS Heart, Lung, and Liver—each with Pre-Market Approval (PMA) for both brain-death (DBD) and circulatory-death (DCD) donors.

Revenue Model: TransMedics Group makes money from sales of OCS products (liver, lung, and heart), participation in clinical trials, and services like its National OCS Program. It made \$441.5 million in 2024, of which 62% came from devices and disposable kits and 38% from services. Disposable parts and services generate recurrent revenue per transplant, whereas devices are mostly one-time sales. With more than 3,700 cases a year, the organization is moving toward procedure-based revenue that is predictable, scalable, and global in scope.

Operating Segment


Segments	Revenue (Millions)	% of Revenue
Liver Organ Care System	\$ 460.50	76.05 %
Heart Organ Care System	\$126.00	20.81%
Lung Organ Care System	\$14.90	2.46%
Other Services	\$4.10	0.68 %

Key Operating Metrics

- **OCS Utilization & Adoption:** 26%(US Transplant Penetration)
- **Organ Segments:** Liver(41% Y-o-Y fast growth), Heart(14% Y-o-Y), Lung(5% Y-o-Y)
- **Operating Income:** \$108.58 Million That indicate expanding profitability.
- **Operational Focus:** NOP (National OCS Program), Aviation Logistics and Clinical Trials
- **OCS Enhance and DENOVO Lungs Trials:** Received FDA Approval

Industry Overview

The global healthcare sector spans hospitals, pharmaceuticals, devices, and insurance, growing at 6–7% annually. The market is rapidly digitizing, with healthcare services projected to reach \$9.34 trillion in 2026 and over \$11.3 trillion by 2030 (4.9% CAGR). AI is transforming the industry, expected to grow from \$39 billion in 2025 to \$504 billion by 2032.



Trends

- Key Growth Drivers:** It include the aging population (1 in 6 people will be over 60 by 2030) and chronic illnesses, which account for around 74% of deaths worldwide.
- Regulatory Influences:** Around the world, governments are tightening data privacy and Policies.
- Technological Advancements:** As telemedicine and wearables become more popular, AI in healthcare is expected to increase from \$39 billion in 2025 to \$504 billion in 2032.
- Consumer Behavior:** More than 60% of patients favour digital-first services

Main Competitors

Firm	Ticker	Market Cap(TTM)	Additional Notes
XVIVO Perfusion	XVIVO	\$0.8 Billions	Pure player of organ equipment of Lungs and Liver and direct competitor of TMDX
Medtronic Plc	MDT	\$111.97 Billions	Focus new innovation AI-driven surgery and robotic assistance.
Stryker Corporation	SYK	\$129.89 Billions	A large cap premium MedTech leader (orthopedics, surgery, neurotech)

Company Positioning

TMDX is a fast-growing disruptor in the organ transplant industry, creating an integrated ecosystem by fusing logistics, airline-based organ transport, and their OCS perfusion technology. The closest direct rival is XVIVO, which uses a more conventional medtech approach and focuses mostly on organ perfusion devices, particularly in the lungs. Large, diverse leaders in the medical technology industry, Medtronic (MDT) and Stryker (SYK), do not directly compete in organ preservation technology; rather, they compete indirectly for hospital funding.

Valuation

Current Valuation: \$3.95 Billion Aprox.

	Prev. Year (FY2024-25)	Current Year (TTM FY25-26)	Next Year (Projected)
EV/Revenue	5.69x	7.25x	5.30x – 5.43x
P/S	4.64x	6.42x	5.16x – 5.37x
Market Cap	\$2.09 Billion	\$3.9 Billion	\$4.16-\$4.20 Billion USD (Analyst Estimated)

Peer Comparison

Company	EV/Revenue	P/S	Market Cap(TTM)
TransMedics	7.25x	6.42X	\$3.9 Billions
XVIVO Perfusion	5.72x	8.89X	\$0.8 Billions
Medtronic PLC	3.91x	3.18X	\$111.97 Billions
Stryker Corp.	5.88x	5.29x	\$129.89 Billions

Valuation Scenarios

Scenario	Assumption	Implied Value Per Share	Upside/Downside
Base Case	P/S multiple 6.5x-6.7x	\$140-145 per share	+20-23% Fairly valued(Steady NOP Expansion in Europe)
Bull Case	P/S multiple 8.5x-8.7x	\$190-200 per share	+65-67% Upside(Target to launch NOP in Italy)
Bear Case	P/S multiple 3.3x-3.5x	\$76-80 per share	-30-33% Downside(Aviation costs erode margins; NOP adoption slows to <15% growth.)

Quantitative Analysis (Financial Health)

In FY2024-25,

Income Statement: TransMedics shows strong financial improvement with revenue rising in 2025 with \$605.5 million in revenue (up 37%) shows rapid adoption of its organ transport technology. Profitability has improved significantly, with operating income of \$108.6 million proves the business model works and positive net income of \$190.3 million.

Balance Sheet: The company is in its strongest financial position to date, with \$1.07 billion in total assets and a massive cash reserve of \$488.4 million. While it carries low bankruptcy risk despite moderate convertible debt \$452.8 million, its high current ratio of 7.14 means it has more than enough liquidity to cover short-term obligations.

Cash Flow Statement: TMDX have cash balance \$488.33 million which is the most remarkable change. In 2025, the firm reported a positive Free Cash Flow of \$133.6 million due to a roughly 300% increase in operating cash flow to \$192.8 million.

Key Ratios

In FY2024-25, TransMedics Group(TMDX) has significant premium valuation and low-margin, high-efficiency ratios.

TransMedics (TMDX) presents a high-growth financials and profitability with P/E ratio of 23.26 and a P/S ratio of roughly 7.47, it reflecting a premium for its market-leading position.

Profitability ratios are Return on Equity (ROE) of over 40% and a Net Profit Margin of 31.4%, though investors should note these were bolstered by 2025 tax credits.

The company's solvency ratios remain robust, evidenced by a Current Ratio of 7.14, providing massive liquidity for operations. While the Debt-to-Equity ratio of 1.06 shows moderate leverage, it is well-supported by rapid growth metrics, including a 37% revenue surge and triple-digit EPS growth over the past year.

Quantitative Analysis (Business Fundamentals)

TransMedics (TMDX) maintains a robust fundamental profile, led by founder Dr. Waleed Hassanein's successful transition from R&D to profitable operations. Its "razor-blade" business model—selling OCS consoles and high-margin consumables—is fortified by an end-to-end logistics moat through the National OCS Program (NOP). By owning the aviation and clinical infrastructure, TMDX holds a dominant market share that traditional competitors cannot easily replicate. While trading at a growth premium, the company's extensive patent portfolio and favorable regulatory tailwinds in organ preservation position it to capitalize on the rising global demand for transplantable organs, ensuring long-term viability despite emerging sector competition. As of April 2026, the expansion of the TransMedics (TMDX) aviation fleet to 22 owned aircraft serves as both a primary revenue driver and a temporary headwind for operating margins.

Price Action and Charts

At the latest close, TMDX stock closed at \$113.36 (prev. \$114.00), with a high of \$115.65 and low of \$110.94. The stock has down -0.64 (0.56%) in one day. This stock traded in NASDAQ index with beta of 0.26 in 1 year, indicating slightly volatility. Volume is 892.4K (1-day) and 1.0M (1-month). It is currently in a short-term uptrend, recovering from recent lows to trade above its 200-day moving average. While rising volume confirms this bounce, resistance near \$115 and a bearish MACD suggest potential near-term consolidation.



Common Technical Indicators

The technical indicators of TransMedics (TMDX) is now neutral to negative. The stock is currently trading at \$113.36, below its 200-day moving average (\$123.67) and 50-day moving average (\$124.18), suggesting that recent advances are being constrained by medium and long-term resistance levels. The MACD is still in negative area, but its histogram displays a bullish divergence, indicating that the current downward trend is waning. Momentum is gradually changing. The stock is neither overbought nor oversold, as indicated by the RSI's neutral 51.67 position. Bollinger Bands show a return to volatility as the price moves from the lower support of \$92.38 to the upper resistance of \$124.67. To verify a positive turnaround, investors should keep an eye out for a persistent break over \$125.

Core Assumption

Three fundamental pillars of TransMedics' (TMDX) technical analysis indicate that the stock is at a significant psychological turning point. First, the recent price volatility demonstrates the idea that the market discounts everything; the steep decline to \$92.38 and the subsequent recovery represented all known basic data, including the most current trial acceptance rates. Second, TMDX is trying to move from a medium-term downturn into a new short-term recovery based on the idea that prices move in trends. Finally, as the market tests the 200-day moving average (\$123.67), the idea that history repeats itself is evident. In the past, this level has served as a "line in the sand" where buyer psychology changes from fear to accumulation, possibly indicating a reversal of trends.

Conclusion/Recommendation

Investment Recommendation

Strong Buy and Hold

Core Thesis Summary

TMDX is a long-term, high-conviction investment with certain forecasts indicating substantial potential by 2026–2030, providing management successfully expands margins and extends its logistics platform internationally. The stock is sometimes considered "AI-immune" because of its emphasis on specialized, physical logistics services. In 2025, revenue reached \$605 million (+37% YoY) with 5,139 cases (+38%). Adoption of the service model, liver expansion, and infrastructure with 22 aircraft are the main drivers of growth. Its investment pillars are primarily the enormous TAM expenditure, vertical integration program (NOP), and disruptive technology of OCS.

Key Risks:

Regulatory Hurdles: Delays in FDA or international approvals and Increased regulatory scrutiny, audits, or legal investigations

Clinical Trial Failure: Uncertain outcomes in ongoing or future clinical trials, Safety issues and slower commercialization

Competitive Threats: Entry of new organ preservation technologies and risk due to better and cheaper alternative price and quality

Regulatory Hurdles: Pressure from insurers/governments on pricing and Stock volatility due to market sentiment or legal concerns

Target Price & Potential Returns

Target Price: \$175.00 to \$190.00

Potential Upside: 54%–68%

Key Catalysts

- In FY 26-27: Transmedics Group run will launch OCS kidney program and Next-Gen OCS platform with low cost.
- The high impact clinical trials on heart with FDA approved (more than 650 patients) and DENOVO Lungs trials by 2027.
- Expansion of TAM market with Italy with replicating U.S logistics model.
- It collaboration with Organ Procurement organization

Key Financial Metrics

Revenue: 605.5 Million USD

EBITDA Margin: 22.2%

Cash Balance: 488.37 Million USD

Market Cap: \$3.91 Billion USD

P/E Ratio: 23.26

EPS: 4.87 USD

Company Snapshot

Ticker: TMDX

Current Price: 113.36 USD

Stock Type

Asset Class: Growth

Size: Mid Cap

Dividend: No

Sources:

Company Filings

- TransMedics Group Inc. Form 10-K (Latest Annual Report), U.S. Securities and Exchange Commission (SEC)
- TransMedics Group Inc. Form 10-Q (Most Recent Quarterly Filing), SEC
- TransMedics Group Inc. Earnings Press Releases & Investor Presentation
- TransMedics Group Inc. website : <https://www.transmedics.com/>

Financial Data & Market Information

- Bloomberg Terminal
- Yahoo Finance and Stock analysis – TransMedics Group Inc.(TMDX)
- Nasdaq.com – TransMedics Group Inc. Historical Price & Valuation Data
- Macrotrends – Historical Revenue & Financial Metrics
- Koyfin / Seeking Alpha – Financial Ratio Data

Industry & Competitive Landscape

- IBISWorld – Healthcare Industry Reports
- Gartner Research –Healthcare and Medical Equipment Industry Analysis
- Statista – Healthcare Market Growth Projections
- Company Filings of Peer Firms (XVIVO, Medtronic, Stryker)

Macroeconomic Data

- U.S. Bureau of Economic Analysis (BEA)
- Federal Reserve Economic Data (FRED)
- U.S. Bureau of Labor Statistics (BLS)

ESG & Governance

- TransMedics Group Inc. Global Sustainability & Governance Reports
- SEC Proxy Filings (DEF 14A)